Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert
Perez, EVP and COO, will present on Wednesday, August 12, 2009 at 11:30
a.m. Eastern Time at the Canaccord Adams 29th Annual Global
Growth Conference at the InterContinental Hotel in Boston, Mass. This
presentation will include discussion of the company’s business
activities, financial outlook, and current news.
A live webcast of the presentation will be accessible through Cubist’s
website at www.cubist.com
in the Investor Relations Conference Calendar section. The webcast will
be available on Cubist’s website for a period of 30 days after the
presentation.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the research, development, and commercialization of pharmaceutical
products that address unmet medical needs in the acute care environment.
In the U.S., Cubist markets CUBICIN® (daptomycin for
injection), the first antibiotic in a new class of anti-infectives
called lipopeptides. In July 2008, Cubist began promoting MERREM®
I.V. (meropenem for injection) in the United States. MERREM is an
established broad spectrum antibiotic developed by AstraZeneca. The
Cubist product pipeline includes ecallantide, a recombinant human
protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the
reduction of blood loss during cardiac surgery, and two Phase 1
programs that address unmet medical needs, one in CDAD (Clostridium
difficile-associated diarrhea) and the other in multi-drug resistant
(MDR) Gram-negative infections. In addition, the Company, in
collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a
pre-IND and a Phase 2 program underway in novel treatments for
respiratory syncytial virus infections using Alnylam’s RNA-interference
technology. Cubist is headquartered in Lexington, MA. Additional
information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals,
Inc.
AstraZeneca and MERREM are registered trademarks of the AstraZeneca
group of companies.
Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior
Director, Corporate Communications
eileen.mcintyre@cubist.com
or
Weber
Shandwick
Tara Murphy, 617-520-7045
tara.murphy@webershandwick.com
